All In Biotech

Drug Trial Radar · NCT07813039

A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation

A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability of a Tablet Formulation of VX-581 in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

16

Actual

Start

Sep 23, 2026

Primary completion

Oct 27, 2026

Study completion Oct 27, 2026

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the relative bioavailability of VX-581 tablet formulation compared to a suspension formulation along with its safety and tolerability.

Conditions

  • Cystic Fibrosis

Interventions

  • VX-581Drug

    Tablet and Suspension for Oral Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of VX-581Time frame: Period 1 and Period 2: From Day 1 up to Day 21
  2. Area Under the Concentration Versus Time Curve (AUC) of VX-581Time frame: Period 1 and Period 2: From Day 1 up to Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion - Tempe

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.